FDA Moves to Exclude Semaglutide, Tizerpatide, and Liraglutide from 503B Bulk Substances List Lengea BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with The Sikiric Problem: One Lab, Thirty Years, Zero Trials That Matter FDA Peptide Reclassification 2026: What Researchers Want Dr Jesse Morse explains why BPC 157 will never receive FDA approval despite its potential to accelerate healing and recovery from injuries. >> More